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Abstract
Background: Few data are available concerning the impact of gender on temporal trends in patients with acute 
ST-segment elevation myocardial infarction (STEMI).
Methods: All STEMI patients consecutively enrolled in the AMIS (Acute Myocardial Infarction in Switzerland) Plus project 
from 1997−2011 were included. Temporal trends in presentation, treatment and outcomes were analyzed using multiple 
logistic regressions with generalized estimations.
Results: Of 21,620 STEMI patients, 5786 were women and 15,834 men from 78 Swiss hospitals. Women were 8.6 
years older, presented 48 minutes later with less pain, but more dyspnea, and more frequently had atrial fibrillation (5.5 
vs. 3.9%, p<0.001), heart failure (Killip class >2) (9.7 vs. 7.3%, p<0.001), and moderate or severe comorbidities (24.8 
vs. 18.2%, p<0.001). Women were less likely to undergo primary reperfusion treatment after adjustment for baseline 
characteristics and admission year (OR 0.80, 95% CI 0.71−0.90, p<0.001) or receive early and discharge drugs, such 
as thienopyridines, angiotensin-converting-enzyme inhibitors, angiotensin II receptor antagonists, and statins. In 1997, 
thrombolysis was performed in 51% of male and 39% of female patients; its use rapidly decreased during the 1990s and 
has now become negligible. Primary percutaneous coronary intervention increased from under 10% in both genders 
in 1997 to over 70% in females and over 80% in males since 2006. Patients admitted in cardiogenic shock increased by 
8% per year in both genders. The incidence of both reinfarction and cardiogenic shock developing during hospitalization 
decreased significantly over 15 years while in-hospital mortality decreased from 10 to 5% in men and from 18 to 7% in 
women. This corresponds to a relative reduction of 5% per year for males (OR 0.95, 95% CI 0.92−0.99, p=0.006) and 
6% per year for female STEMI patients (OR 0.94, 95% CI 0.91−0.97, p<0.001). Despite higher crude in-hospital mortality, 
female gender per se was not an independent predictor of in-hospital mortality (OR 1.07, 95% CI 0.84−1.35, p=0.59).
Conclusion: Substantial changes have occurred in presentation, treatment, and outcome of men and women with STEMI 
in Switzerland over the past 15 years. Although parallel trends were seen in both groups, ongoing disparities in certain 
treatments remain. However, these did not translate into worse risk-adjusted in-hospital mortality, suggesting that the 
gender gap in STEMI care may be closing.
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Introduction
Numerous advances in the treatment of acute ST-elevation 
myocardial infarction (STEMI) have occurred over the last 
few decades. In the early 1980s, acute reperfusion therapy 
with fibrinolytic agents was first introduced along with 
aspirin therapy and beta-blockers.1 Subsequent clinical tri-
als in the 1990s first began to demonstrate the superiority of 
primary percutaneous coronary intervention (PCI) as an 
alternative method for acute reperfusion therapy when per-
formed in a timely manner and by experienced operators.2,3 
Thanks to the Stent for Life initiative of the European 
Association for Percutaneous Cardivascular Intervention 
(EAPCI) and the Working Group on Acute Cardiac Care 
(ESC), primary PCI has already become the dominant rep-
erfusion therapy in the majority of European countries.4 
The management of STEMI has advanced even further in 
recent years and now includes additional treatments as 
well, including dual antiplatelet therapy with thienopyri-
dines, early statin use, and angiotensin-converting-enzyme 
(ACE) inhibitors and angiotensin-II receptor (AT) antago-
nists in selected patients.5−7
Despite these advances, STEMI remains an important 
cause of mortality and morbidity in the general popula-
tion worldwide, and the application of evidence-based 
therapies for STEMI patients in real-world practice con-
tinues to be inconsistent.8 This last concern is particularly 
true for specific populations, such as women, where dis-
parities in care have been shown in earlier studies.9−11 
Whether such disparities between men and women are 
decreasing over time is uncertain but they are important 
for policymakers and providers to understand as the num-
ber of evidence-based therapies has grown. If disparities 
remain, then areas of focus could be identified for future 
quality improvement efforts within organized STEMI 
systems of care. A specific challenge to understanding 
this issue is finding comprehensive, national data sources 
that also include detailed clinical information. A recent 
Swedish study evaluated gender differences in treatment 
and outcome of STEMI patients in 1998−2000 vs. 
2004−2006.12 A newer study from a nationwide STEMI 
network program in Belgium evaluated changes in reper-
fusion therapy and outcome between 2007−2008 and 
2009−2010.13
Accordingly, we used the Acute Myocardial Infarction 
in Switzerland (AMIS) Plus registry to evaluate temporal 
trends in presentation, treatment, and outcome in men and 
women with STEMI in Switzerland between 1997 and 
2011. The advantages of the AMIS Plus registry include its 
inclusiveness and rich data sources that allow for detailed 
assessments of processes of care and in-hospital outcomes. 
Further, use of the AMIS Plus registry provides insights 
into these trends in STEMI patients from central Europe, an 
area of the world that is relatively underrepresented in ear-
lier studies.
Methods
The AMIS Plus project founded in 1997 is an ongoing 
nationwide prospective registry of patients admitted with 
ACS to hospitals in Switzerland with the goal to under-
stand the transfer, use, and practicability of knowledge 
gained from randomized trials and to generate input for 
subsequent prospective and randomized studies. Details 
have been previously published.14−17 From 106 hospitals 
treating ACS in Switzerland, 78 hospitals temporarily or 
continuously enrolled patients in AMIS Plus. Participating 
centers, ranging from community institutions to large ter-
tiary facilities, provided blinded data for each patient 
through standardized internet- or paper-based question-
naires using the most up-to-date information technology. 
Participating centers are strongly encouraged to enrol all 
patients fulfilling the inclusion criteria to avoid selection 
bias. Hospital data were provided and completed by the 
treating physician or a trained study nurse. All data were 
checked for completeness, plausibility, and consistency by 
the AMIS Plus Data Center in the Institute of Social and 
Preventive Medicine at the University of Zurich and treat-
ing physicians or study nurses were queried when neces-
sary. The registry was approved by the Supra-Regional 
Ethics Committee for Clinical Studies, the Swiss Board for 
Data Security, and the Cantonal Ethics Commissions. The 
AMIS Plus project was officially supported by the Swiss 
Societies of Cardiology, Internal Medicine, and Intensive 
Care Medicine.
The questionnaire had 230 items that addressed medical 
history, comorbidities, known cardiovascular risk factors, 
clinical presentation, out-of-hospital management, early 
in-hospital management, reperfusion therapy, hospital 
course, used or planned diagnostic tests, length of stay, 
discharge medication, and discharge destination. Patients 
were enrolled in the registry on the basis of their final 
diagnosis.
In this study, the following therapies were studied: 
immediate drug (defined as therapy received within 24 
hours after admission), reperfusion (thrombolysis or pri-
mary PCI), and discharge medication. Risk factors were 
documented in the patient’s medical history: dyslipidemia, 
arterial hypertension and diabetes were assigned if the 
patient had been previously treated and/or diagnosed by a 
physician. Documentation of the risk factors provided by 
the local physicians was accepted as stated. Patients were 
defined as obese if the body mass index was ≥30 kg/m2 and 
as smokers if the patient was a smoker at the time of the 
cardiovascular event. Comorbidities of the patients were 
assessed using the Charlson index.18 Reinfarction was 
defined as clinical signs or symptoms of ischemia with 
ECG changes indicative of new ischemia (new ST-changes 
or new left bundle branch block) and a re-rise of biomark-
ers following the initial infarction. A cerebrovascular event 
was defined as any event due to ischemic, thrombotic, or 
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hemorrhagic disturbances confirmed by a neurologist or 
imaging modality.
The primary outcome measure was in-hospital mortal-
ity. Secondary outcome measures were the rates of in-hos-
pital major adverse cardiac or cerebrovascular events, 
defined as a composite endpoint of mortality, reinfarction, 
and cerebrovascular events.
Patient selection
The present analysis included all patients enrolled in AMIS 
Plus between January 1997 and December 2011, with 
STEMI defined by characteristic symptoms and/or ECG 
changes and cardiac marker elevation (either total creatine 
kinase or creatine kinase MB fraction at least twice the 
upper limit of normal or troponin I or T above individual 
hospital cut-off levels for myocardial infarction) and 
ST-segment elevation and/or new left bundle branch block 
on the initial ECG.
Statistical analysis
The results are presented as percentages for categorical 
variables and analyzed using the non-parametric Pearson χ2 
test or Fisher’s Exact test as appropriate. Continuous nor-
mally distributed variables are expressed as mean±1 stand-
ard deviation and compared using the Student’s two-tailed 
unpaired t-test. Continuous non-normally distributed vari-
ables are expressed as median and interquartile ranges and 
analyzed using the Mann−Whitney U test. To analyze tem-
poral trends of continuous variables the Spearman rank cor-
relation and linear regression were used. A probability 
value <0.05 was considered significant.
Temporal trends in treatment and outcomes were calcu-
lated using multiple logistic regression models. These mod-
els determined the use of immediate reperfusion and the 
early administration of evidence-based drugs according to 
gender, and included the following variables: age, Killip 
class >2, the risk factors smoking, dyslipidemia, hyperten-
sion, and diabetes, Charlson comorbidity weighted index 
>2, and admission year. To determine in-hospital mortality 
predictors, a multivariate logistic regression model included 
the following variables: age, sex, Killip class >2, the risk 
factors smoking, dyslipidemia, hypertension, and diabetes, 
Charlson comorbidity weighted index >2, and admission 
year. To address clustering of patients within hospitals, 
logistic regressions with robust standard error and hospital 
ID as cluster were performed to analyze the effect of gender 
treatment used and the effect of different covariables on 
in-hospital mortality using Stata 11.2 (StataCorp, College 
Station, TX, USA).19,20
SPSS software (version 19; SPSS, Chicago, IL, USA) 
was used for all other statistical analyses.
Results
Between 1997 and 2011, a total of 21,620 patients with 
STEMI were enrolled in the AMIS Plus registry. Of these, 
5786 (27%) were females and 15,834 (73%) were males. 
Baseline characteristics are shown in Table 1. Compared 
with men, women were 8.6 years older (71.5±12.6 vs. 
62.9±13.0 years) with increased comorbidities (Charlson 
Index ≥2 24.8 vs. 18.3%, p<0.001). Women had more fre-
quently diabetes (22.4 vs. 17.3%, p<0.001) and hyperten-
sion (65.0 vs. 50.8%, p<0.001), but similar frequencies of 
coronary artery disease (30.1 vs. 31.5%, p=0.08). Women 
with STEMI presented 48 minutes later with less pain (85.2 
vs. 88.4%, p<0.001) and more dyspnea (32.9 vs. 25.3%, 
p<0.001), had more frequently Killip class >2 (9.7 vs. 
7.3%, p<0.001) and atrial fibrillation (5.5 vs. 3.9%, 
p<0.001). Men with STEMI had more frequently dyslipi-
demia (53.8 vs. 49.8%, p<0.001), were more often current 
smokers (46.3 vs. 29.9%, p<0.001), and were more likely 
to have resuscitation prior to admission (6.3 vs. 5.3%, 
p=0.004).
The percentage of female STEMI patients remained 
relatively constant during the examined period of 15 years 
(OR 0.99, 95% CI 0.98−1.00, p=0.21). The mean age of 
male STEMI patients decreased slightly (regression coef-
ficient B −0.06/year, 95% CI −0.14 to −0.02/year, p=0.16), 
but there was no change seen for female patients (B +0.02/
year, 95% CI −0.11 to +0.14/year, p=0.79). The percentage 
of patients who presented with cardiogenic shock increased 
per year in both genders (male: OR 1.08, 95% CI 1.03−1.13, 
p=0.003; female: OR 1.08, 95% CI 1.03−1.12, p=0.001), 
whereas those with moderate to severe comorbidities 
(Charlson weighted index ≥2) slightly decreased in males 
(OR per year 0.98, 95% CI 0.96−1.00, p=0.09), but not in 
females (OR per year 1.00, 95% CI 0.97−1.04, p=0.97).
Delay between symptom onset and admission decreased 
between 1997 and 2011 in both gender significantly: in 
males from 218 min (IQR 120−640) to 169 min (IQR 
100−375, p<0.001) and in females from 287 min (IQR 
136−870) to 207 min (IQR 120−418min, p<0.001).
Trends in therapies
Female STEMI patients were less likely to undergo pri-
mary reperfusion (thrombolysis or PCI) than their male 
counterparts (62.2 vs. 75.9%, OR 0.52, 95% CI 0.49−0.56, 
p<0.001) even after adjustment for baseline characteristics 
and admission year (OR 0.80, 95% CI 0.71−0.90, p<0.001). 
After adjustment for all differences, female patients with 
STEMI were also less likely to receive most early and dis-
charge drug therapies, such as thienopyridines, ACE inhibi-
tors, and/or AT antagonists or statins (Figure 1).
About 25−32% of patients needed to be transferred for 
intervention and this percentage did not change during the 
examined period.
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In 1997, thrombolysis was performed in 51% of male 
and 39% of female STEMI patients. This decreased con-
tinuously and was negligible in the last few years. In con-
trast, from 1997 to 2006, primary PCI was performed 
increasingly in both genders, from under 10% to over 70% 
in females and over 80% in males and since then has 
remained relatively constant (Figure 2).
Door-to-balloon time for primary PCI decreased 
between 2000 and 2011 for male STEMI patients from 51 
min (IQR 29−135) to 43 min (IQR 16−90, p<0.001) and 
more prominently for females from 80 min (IQR 26−237) 
to 48 min (IQR 18−97, p<0.001). Therefore, the difference 
between men and women was no longer significant in 2011 
(p=0.48).
The trends in early drug therapy are depicted in Figure 
3a. Thienopyridine use as early drug therapy consistently 
increased. Since 2008, it was administered to over 90% of 
males and over 80% in females. Early statin use increased 
rapidly up until 2002, with a peak use of 72% in females 
and 82% in males in 2005−2006. Afterwards there was a 
slight decrease in statin use within the first 24 hours.
However, since 2008, the prescription of statins at dis-
charge has continuously increased to over 95% in men and 
89% in women. Thienopyridine use at discharge also 
increased and was prescribed to over 92% of all STEMI 
patients in 2011 (Figure 3b).
In-hospital outcome
Overall, female STEMI patients had a higher rate of com-
plications and higher crude in-hospital mortality. However, 
cardiogenic shock developing during hospitalization and 
Table 1. Baseline characteristics of patients admitted with ST-elevation myocardial infarction according to gender (n=21,620)
Male Female p-value
Patients 15,834 (73) 5786 (27)  
Age (years) 62.9±13.0 71.5±12.6 <0.001
Delay (h:min) 3:10 (1:40 to 8:00) 3:58 (2:01 to 10:23) <0.001
Resuscitation prior admission
 Cardiopulmonary resuscitation 737/15,466 (4.8) 218/5648 (3.9) 0.005
 Cardioversion/defibrillation 805/15,382 (5.2) 216/5620 (3.8) <0.001
Symptoms at admission
 Pain 13,569/15,346 (88.4) 4778/5608 (85.2) <0.001
 Dyspnea 3562/14,067 (25.3) 1707/5190 (32.9) <0.001
Vital signs at admission
 Systolic blood pressure (mmHg) 133.5±27.5 134.4±30.0 0.06
 Heart rate (beats/min) 78.2±20.1 80.8±21.9 <0.001
Systolic blood pressure ≤90 mmHg 815/15,628 (5.2) 400/5724 (7.0)) <0.001
Heart rate >100 beats 1722/15,609 (11.0) 843/5735 (14.7) <0.001
Heart rhythm
 Sinus rhythm 12,225/13,206 (92.6) 4303/4757 (90.5) <0.001
 Atrial fibrillation 510/13,206 (3.9) 264/4757 (5.5) <0.001
Killip class n=15,643 n=5709  
 I 12,408 (79.3) 4060 (71.1) <0.001
 II 2090 (13.4) 1096 (19.2)  
 III 549 (3.5) 329 (5.8)  
 IV 596 (3.8) 224 (3.9)  
Risk factors
 Smoking 6805/14,691 (46.3) 1553/5192 (29.9) <0.001
 Dyslipidemia 7593/14,112 (53.8) 2453/4925 (49.8) <0.001
 Hypertension 7593/14,935 (50.8) 3573/5499 (65.0) <0.001
 Diabetes 2623/15,149 (17.3) 1230/5494 (22.4) <0.001
 Obesity 2407/12,830 (18.8) 820/4361 (18.8) 0.95
Coronary artery disease 4488/14,269 (31.5) 1567/5201 (30.1) 0.08
Charlson weighted index n=11,373 n=4084  
 0 (no comorbidities) 6922 (60.9) 2128 (52.1) <0.001
 1 2371 (20.8) 944 (23.1)  
 2 983 (8.6) 495 (12.1)  
 ≥3 1097 (9.6) 517 (12.7)  
Values are mean±SD, median (interquartile range), n/total (%), or n (%).
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reinfarction decreased significantly during these 15 years in 
both genders (all p<0.001; Figure 4a).
The duration of hospital stay decreased from 10 days for 
men and 12 days for women in 1997−1998 to 4 days and 6 
days, respectively, in the last 3 years (both p<0.001).
Trends in crude in-hospital mortality in both genders are 
shown in Figure 4b. Over 15 years, crude in-hospital mor-
tality decreased from 10 to 5% in men and from 18 to 7% 
in women. This corresponds to a relative reduction of 5% 
per year for males (OR 0.95, 95% CI 0.92−0.99, p=0.006) 
and 6% per year for female STEMI patients (OR 0.94, 95% 
CI 0.91−0.97, p<0.001). Female gender was not an inde-
pendent predictor of in-hospital mortality (OR 1.07, 95% 
CI 0.84−1.35, p=0.59; Table 2).
Discussion
Our study has several key findings. First, in-hospital mor-
tality has been halved among men and women with STEMI 
during the last 15 years in Switzerland. Furthermore, we 
identified important overall trends in the presentation and 
treatment in both gender. It is noteworthy, for example, that 
we found women presented at an older age, after greater 
delay, and in a sicker condition overall. These findings are 
consistent with work in other regions of the world.21
Second, the baseline characteristics of the STEMI 
patients changed in both genders during the observed 
period of 15 years. The mean age of women remained the 
same during this period, but male patients became slightly 
younger. In addition, a growing proportion of STEMI 
patients were admitted in cardiogenic shock, increasing 
between 1997 and 2011 in both genders to 8% per year. 
This could be related to better STEMI patient selection 
Figure 1. Adjusted OR for immediate therapies (A) and 
discharge drugs (B) received by female patients with acute 
ST-segment elevation myocardial infarction (reference 
group: male). Adjusted for age, Killip classes>2, risk 
factors (smoking, dyslipidemia, hypertension, diabetes) and 
comorbidities (Charlson weighted index ≥2) and  
admission year
Primary reperfusion, thrombolysis or primary percutaneous coronary 
intervention; ACE, angiotensin-converting enzyme; AT, angiotensin-II 
receptor; LMWH, low-molecular-weight heparin.
Figure 2. Trends in reperfusion therapies in male and female patients with acute ST-segment elevation myocardial infarction in 
Switzerland between 1997 and 2011
F, female; M, male; PCI, primary percutaneous coronary intervention.
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leading to a reduction in out-of-hospital deaths. Rates of 
cardiogenic shock at admission in ACS patients remained 
constant up until 2006.14
Finally, we found that important differences between 
men and women persisted when we examined treatment 
patterns. Women were significantly less likely to receive 
primary reperfusion and evidence-based therapies. Yet 
these differences in treatment did not translate into higher 
risk-adjusted mortality among women.
These findings complement and extend work by other 
groups. Between 1995 and 2006, for example, risk-stand-
ardized 30-day mortality rates among over 2.7 million 
elderly patients discharged with acute myocardial infarc-
tion in the USA showed a significant decrease.22 However, 
this study used administrative data and was unable to reli-
ably distinguish between improvements in mortality related 
to STEMI as opposed to non-STEMI. In contrast, Yeh 
and colleagues reported that 30-day mortality improved 
in a large community-based population from Northern 
California over a similar time period for non-STEMI but 
not STEMI patients.23 A prospective observational cohort 
study from the SWEDEHEART registry evaluated gender 
differences in treatment and outcome between the two peri-
ods 1998−2000 and 2004−2006 and found reduced mortal-
ity but a persistent gender gap.12 In the latest Euro Heart 
Survey for acute coronary syndromes, improvements in 
in-hospital mortality were also seen between 2006 and 
2008 among STEMI patients at 138 centers in 21 coun-
tries.24 These findings point toward general improvements 
in STEMI care and were accompanied by increases in the 
number of patients receiving reperfusion therapy, the pro-
portion receiving primary PCI, and the timeliness of insti-
tuting treatments.
Our study showed a dramatic decrease in early mortal-
ity, in cardiogenic shock developing in hospital as well as 
in the reinfarction rates for both gender. Differences existed 
between the two groups at baseline, despite favourable 
changes for both men and women. For comparison, 
Figure 3. Trends in immediate (A) and discharge (B) drug therapies in male and female patients with acute ST-segment elevation 
myocardial infarction in Switzerland between 1997 and 2011
ACE, angiotensin-converting enzyme; AT, angiotensin-II receptor; F, female; GP, glycoprotein; M, male;
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investigators from Denmark recently reported that trends in 
acute myocardial infarction over the last 25 years now 
suggest similar short- and long-term outcomes in men 
and women over the last several years25 − a finding 
that is consistent with our results − yet this study used 
administrative data and was unable to look at measures of 
processes of care, such as the use of evidence-based thera-
pies. Thus, our findings still support the conclusions of the 
Figure 4. Trends in complications during hospitalization (cardigenic shock, reinfarction, and cerebrovascular events; A) and in crude 
mortality and major adverse cardiac and cerebrovascular events (B) in male and female patients with acute ST-segment elevation 
myocardial infarction in Switzerland between 1997 and 2011
Table 2. Independent predictors for in-hospital mortality in patients with acute ST-segment elevation myocardial infarction
OR 95% CI p-value
Female gender 1.07 0.84−1.35 0.59
Age 1.07 1.06−1.09 <0.001
Killip class >2 7.63 5.48−10.63 <0.001
Smoking 1.30 1.03−1.64 0.028
Dyslipidemia 0.89 0.71−1.11 0.31
Hypertension 0.77 0.67−0.89 <0.001
Diabetes 1.13 0.85−1.50 0.40
Charlson weighted index ≥2 1.94 1.58−2.38 <0.001
Admission year 0.97 0.92−1.01 0.052
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EuroHeart project in 2010 that highlighted ongoing dispari-
ties between men and women in cardiovascular care and 
also pushed for understanding reasons behind this complex 
phenomenon.26
A contemporary report from Canada, for example, sug-
gested underutilization of evidence-based therapies among 
women were related to the patient (e.g. age), consequences 
of the disease (e.g. heart failure), and the physician’s assess-
ment of patient risk.27 Finally, Canto and colleagues 
recently described findings from over 1 million patients in 
the National Registry for Myocardial Infarction (NRMI) in 
the USA from 1994 to 2006. In this study, a large propor-
tion of women (~40%) presented without chest pain and 
had worse outcome than men − although these differences 
were attenuated in older age groups.28 Our study extends 
earlier work by systematically examining differences 
between these two groups as well as trends over a long 
period of time with more current data and in a single 
European healthcare system, as opposed to a series of 
‘snapshots’.
What are the implications of our findings? We believe 
that it highlights both recent successes in diminishing dis-
parities between men and women while also pointing out 
ongoing opportunities for further improvement. An impor-
tant example of ongoing opportunities might be seen in the 
use of statin therapy, which was consistently lower in 
women than men. Future programs might target women 
specifically to understand barriers and to ensure that initia-
tion of statin therapy occurs ideally within the hospital set-
ting before discharge. However, a lack of differences in 
in-hospital mortality supports the notion that we have made 
substantial strides as well and that clinicians are making 
reasonable decisions in many circumstances. As future 
work progresses in this area, greater understanding of gen-
der differences in psychosocial factors, cardiovascular risk 
factors, pathophysiological factors, and responses to both 
invasive and medical treatments will be needed.
Our study should be interpreted in the context of the fol-
lowing limitations. First, this study is an observational 
report with temporal and regional heterogeneity of the data. 
Although it included most of the hospitals in Switzerland, it 
was a voluntary program focused on a quality improvement 
initiative. It therefore may represent those facilities with a 
greater desire to benchmark their results in comparison 
with other hospitals. Second, the healthcare system in 
Switzerland differs from other European countries and the 
USA, making these findings difficult to generalize to other 
settings. Third, we tried to account for confounders that 
changed over time, including using total creatine kinase for 
the diagnosis of acute STEMI in the early period of our 
study. While our multivariable models included a number 
of factors, it is likely that some other important conditions 
that might explain differences between men and women 
may have been excluded. Furthermore, there was no long-
term follow up. However, the large number of patients and 
continuity of the AMIS Plus data collection allowed a con-
temporary view of the development of STEMI treatment 
over a long time period in Switzerland.
In summary, we found that in-hospital mortality has 
been halved and that substantial changes have occurred in 
treatment of STEMI among both men and women in 
Switzerland over the last 15 years. For the most part, trends 
developed in parallel across the two groups, although ongo-
ing disparities in treatments remain. These disparities in 
treatment, however, are not associated with worse risk-
adjusted outcomes, suggesting that the gender gap may be 
closing.
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